Table 3.

Characteristics of patients with oral CIC

Patient ID	Oral contraceptive	Age (yr)	Exposure time	Liver parameters					Comments		Genotypes of SNPs
				ALT	AP	γGT	tBili	tBA	Clinical features	Histology	ABCB111331T>C (V444A)	ABCC23600T>A (V1188E)	ABCC24581G>A (C1515Y)
				(ULN)	(ULN)	(ULN)	(ULN)	(ULN)
11	30 μg ethinylestradiol/75 μg gestodene	32	nd	4.9	1.7	1	10.9	22.3	Jaundice	Intrahepatic cholestasis	CC	TT	GG
2	30 μg ethinylestradiol/150 μg levonorgestrel	15	21 d	1	3	1	4.2	nd	Jaundice, nausea, pruritus	Extensive intrahepatic cholestasis	CC	TT	GG
3	35 μg ethinylestradiol/50 μg levonorgestrel	40	2 yr	3.9	2.8	3.6	0.5	1.6	Pruritus	Bland	CC	TT	GG
4	35 μg ethinylestradio/2 mg cyproteron	34	nd	1	1.3	nd	2.8	1.6	Jaundice	Extensive canalicular cholestasis, mild portal inflamation	CC	TA	GA

¹Patient exhibited previous episodes of ICP.